OTCMKTS:IGXT

IntelGenx Technologies - IGXT Stock Forecast, Price & News

$0.16

-0.01 (-5.80%)

(As of 03/20/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.16
▼
$0.17
50-Day Range: $0.16
▼
$0.26
52-Week Range: $0.11
▼
$0.37

Volume: 6,210 shs
Average Volume: 104,747 shs
Market Capitalization: $28.35 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About IntelGenx Technologies (OTCMKTS:IGXT) Stock

IntelGenx Technologies Corp. is a oral drug delivery company, which focuses on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm technology platform. Its products include rizaport, tadalafil, loxapine, and montelukast. The company also offers a comprehensive portfolio of pharmaceutical services, such as pharmaceutical research & development, clinical monitoring, regulatory support, tech transfer & manufacturing scale-up and commercial manufacturing. IntelGenx Technologies was founded on July 27, 1999 and is headquartered in Ville Saint-Laurent, Canada.

Receive IGXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IntelGenx Technologies and its competitors with MarketBeat's FREE daily newsletter.

IGXT Stock News Headlines

February 21, 2023 | finance.yahoo.com

IntelGenx Receives USPTO Notice of Allowance for Loxapine Orange Book Eligible Patent

February 9, 2023 | finance.yahoo.com

IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm® for the Treatment of Parkinson’s Disease

March 20, 2023 | Weiss Ratings (Ad)

Urgent Warning

This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …

January 23, 2023 | finance.yahoo.com

IntelGenx and Arwan Enter into a Supply Agreement for RIZAPORT® in MENA Countries

December 7, 2022 | finance.yahoo.com

IntelGenx Announces Collaboration with UPEI to Evaluate Acceptance and Preference of VetaFilm™ Platform in Dogs and Cats

November 22, 2022 | finance.yahoo.com

IntelGenx Receives FDA PDUFA Date for RIZAFILM®

November 18, 2022 | seekingalpha.com

IntelGenx Technologies Corp. (IGXT) Q3 2022 - Earnings Call Transcript

November 10, 2022 | finance.yahoo.com

IntelGenx Reschedules Third Quarter 2022 Conference Call Due to Technical Issues Experienced Today by Webcast Vendor

March 20, 2023 | Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

November 3, 2022 | markets.businessinsider.com

New Oral Film Tech Improving Cannabinoid Onset Seeks Patent Protection

November 3, 2022 | finance.yahoo.com

IntelGenx to Report Third Quarter 2022 Financial Results on November 10, 2022 – Conference Call to Follow

November 2, 2022 | finance.yahoo.com

IntelGenx Files Provisional U.S. Patent Application for Advanced Oral Film Formulation Improving Cannabinoid Onset of Action

October 25, 2022 | msn.com

Canadian Company's New Version Of Chemo-Induced Pain Treatment Is On FDA Track

October 25, 2022 | finance.yahoo.com

IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

October 13, 2022 | finance.yahoo.com

IntelGenx’s Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an Oral Thin Film Psychedelic Drug Candidate

October 4, 2022 | msn.com

Short Volatility Alert: IntelGenx Technologies Corp.

July 29, 2022 | theglobeandmail.com

Intelgenx Technologies Corp WT stock $verbed on Wednesday.

July 29, 2022 | theglobeandmail.com

Intelgenx Technologies Corp WT stock $verbed on Thursday.

July 5, 2022 | finance.yahoo.com

IntelGenx Announces Completion of Share Issuance in Payment of Principal and Interest on Debentures

May 12, 2022 | finance.yahoo.com

IntelGenx Reports First Quarter 2022 Financial Results

March 26, 2022 | seekingalpha.com

IntelGenx slumps 10% after fourth quarter's results

March 23, 2022 | msn.com

Psychedelic Stock Gainers And Losers From March 23, 2022

March 9, 2022 | msn.com

Psychedelic Stock Gainers And Losers From March 9, 2022

March 8, 2022 | msn.com

Psychedelic Stock Gainers And Losers From March 8, 2022

March 7, 2022 | msn.com

Psychedelic Stock Gainers And Losers From March 7, 2022

February 1, 2022 | finance.yahoo.com

IntelGenx Receives Third Loan Tranche from atai

January 20, 2022 | msn.com

Psychedelic Stock Gainers And Losers From January 18, 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive IGXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IntelGenx Technologies and its competitors with MarketBeat's FREE daily newsletter.

IGXT Company Calendar

Last Earnings: 11/12/2020
Today: 3/20/2023
Next Earnings (Estimated): 3/22/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:IGXT
CUSIP: 45822R101
CIK: 1098880
Web: www.intelgenx.com
Phone: (514) 331-7440
Fax: 514-331-0436
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,320,000.00
Net Margins: -850.04%
Pretax Margin: -850.28%
Return on Equity: -863.97%
Return on Assets: -70.29%

Debt

Debt-to-Equity Ratio: 5.92
Current Ratio: 2.59
Quick Ratio: 2.56

Sales & Book Value

Annual Sales: $1.53 million
Price / Sales: 18.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.03 per share
Price / Book: 5.41

Miscellaneous

Outstanding Shares: 174,650,000
Free Float: 91,235,000
Market Cap: $28.35 million
Optionable: Not Optionable
Beta: 2.48

Key Executives

Horst G. Zerbe
Chairman & Chief Executive Officer

André Godin
President & Chief Financial Officer

Rodolphe Obeid
Chief Operating Officer

Nadine Paiement
Vice President-Research & Development

Dana Matzen
Vice President-Business & Corporate Development

Key Competitors

View All Competitors

IGXT Stock - Frequently Asked Questions

How have IGXT shares performed in 2023?: IntelGenx Technologies' stock was trading at $0.1973 at the start of the year. Since then, IGXT stock has decreased by 17.7% and is now trading at $0.1623.
View the best growth stocks for 2023 here.
Are investors shorting IntelGenx Technologies?: IntelGenx Technologies saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 5,800 shares, an increase of 93.3% from the February 13th total of 3,000 shares. Based on an average trading volume of 214,700 shares, the days-to-cover ratio is presently 0.0 days.
View IntelGenx Technologies' Short Interest.
When is IntelGenx Technologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our IGXT earnings forecast.
How were IntelGenx Technologies' earnings last quarter?: IntelGenx Technologies Corp. (OTCMKTS:IGXT) issued its quarterly earnings data on Thursday, November, 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.01. The company earned $0.51 million during the quarter. IntelGenx Technologies had a negative trailing twelve-month return on equity of 863.97% and a negative net margin of 850.04%.

What other stocks do shareholders of IntelGenx Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IntelGenx Technologies investors own include Cronos Group (CRON), Zevra Therapeutics (KMPH), Exelixis (EXEL), SemiLEDs (LEDS), New Residential Investment (NRZ), Anavex Life Sciences (AVXL), Ampio Pharmaceuticals (AMPE), BioDelivery Sciences International (BDSI), BIOLASE (BIOL) and Ocugen (OCGN).
What is IntelGenx Technologies' stock symbol?: IntelGenx Technologies trades on the OTCMKTS under the ticker symbol "IGXT."
How do I buy shares of IntelGenx Technologies?: Shares of IGXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is IntelGenx Technologies' stock price today?: One share of IGXT stock can currently be purchased for approximately $0.16.
How much money does IntelGenx Technologies make?: IntelGenx Technologies (OTCMKTS:IGXT) has a market capitalization of $28.35 million and generates $1.53 million in revenue each year. The company earns $-9,320,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.
How can I contact IntelGenx Technologies?: IntelGenx Technologies' mailing address is 6420 ABRAMS, VILLE SAINT LAURENT A8, H4S 1Y2. The official website for the company is www.intelgenx.com. The company can be reached via phone at (514) 331-7440, via email at stephen@intelgenx.com, or via fax at 514-331-0436.

This page (OTCMKTS:IGXT) was last updated on 3/20/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial